Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2007

Diosynth Extends Commercial Supply Ageement with PDL BioPharma

  • Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma for the commercial manufacture of Retavase® (reteplase), a fibrinolytic agent that has been marketed in North America since October 1996.

    Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »